证券研究报告：医药生物 | 公司点评报告 发布时间：2026-01-06 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 34.16 | | --- | --- | | 总股本/流通股本（亿股）10.27 | / 7.66 | | 总市值/流通市值（亿元）351 | / 262 | | 周内最高/最低价 52 | 48.80 / 24.86 | | 资产负债率(%) | 45.0% | | 市盈率 | -26.28 | | 第一大股东 | HKSCC NOMINEES | | LIMITED | | 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 君实生物(688180) EGFR/HER3 ADC 双抗进入 II 期临床，联用方案有望 实现弯道超车 l EGFR/HER3 ADC 双抗进入 II 期临床，联用方案可期 事件：公司在 CDE 药物临床试验登记与信息公示平台网站上，登 记了一项 EGFR/HER3 双抗药物 JS212，联合 PD-1 抗体特瑞普利，或 PD-1/VEGF 双抗 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a potential upside in the stock price [2][3]. Core Insights - The company is expected to benefit significantly from the upcoming launch of the game "Yihuan," which is projected to generate over 5 billion RMB in its first year, potentially becoming a key intellectual property (IP) for the company [6]. - The return of the "DOTA2 International Invitation" esports event to Shanghai is anticipated to enhance revenue through event operations and related consumer spending, aligning with the cultural consumption trend [6]. - The company reported a revenue of 1.726 billion RMB in Q3 2025, a year-on-year increase of 31.45%, and achieved a net profit of 162 million RMB, marking a turnaround from previous losses [6]. - Cost reduction and efficiency improvements have been implemented, with a significant reduction in R&D personnel, which is expected to enhance future productivity [6]. Financial Summary - The company forecasts net profits of 876 million RMB, 1.415 billion RMB, and 1.668 billion RMB for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 61.5% and 17.9% [8]. - Earnings per share (EPS) are projected to be 0.45 RMB, 0.73 RMB, and 0.86 RMB for the same years, with corresponding price-to-earnings (P/E) ratios of 37, 23, and 20 [8]. - The company’s revenue is expected to grow from 7.306 billion RMB in 2025 to 10.219 billion RMB in 2026, reflecting a positive growth trajectory [10].

Investment Rating - The report initiates coverage on Huaming Equipment with a "Buy" rating, assigning a target price of 29.5 RMB based on a 30.4x PE for 2026 [3][8][15]. Core Views - Huaming Equipment ranks first in the domestic transformer tap changer industry and second globally, with a robust growth outlook driven by overseas expansion, maintenance services, and ultra-high voltage (UHV) business [3][15]. - The global power grid investment is entering an upward cycle, which is expected to boost the company's performance significantly, with a projected CAGR of 18.7% for net profit from 2025 to 2027 [3][15]. - The company is transitioning from a "device manufacturer" to a "full lifecycle service provider," leveraging its high installed base for maintenance services, which presents substantial growth potential [5][18]. Summary by Sections Investment Outlook - The report highlights that global power grid investments are on the rise, with significant constraints on overseas power equipment supply. The company’s export scale is expected to grow, with direct and indirect exports projected at 3.4 billion, 4.9 billion, and 3.1 billion RMB for 2023, 2024, and the first half of 2025, respectively, reflecting year-on-year growth of 61.9%, 42.6%, and 45.3% [4][16]. - The company is actively exploring opportunities in Europe, Southeast Asia, and North America, with a focus on localized layouts and customized solutions [4][16]. Ultra-High Voltage and Maintenance Services - The domestic ultra-high voltage market is anticipated to grow significantly, with the company expected to capture a 60% market share, translating to an additional revenue of 2.2 billion RMB during the 14th Five-Year Plan period [5][17]. - The maintenance business is projected to reach a potential revenue scale of 7 billion RMB, with a significant increase in orders expected in the coming years [18]. Competitive Advantages - The company maintains a high gross margin, consistently above 55% since 2019, attributed to its strong market position and R&D capabilities, which create substantial barriers to entry for competitors [6][19]. - Huaming Equipment's comprehensive manufacturing capabilities, with 80% of components produced in-house, enhance its cost control and supply chain stability, particularly advantageous during periods of overseas market tightness [6][19]. Financial Projections - The report forecasts net profits of 7.30 billion, 8.66 billion, and 10.28 billion RMB for 2025, 2026, and 2027, respectively, with corresponding EPS of 0.81, 0.97, and 1.15 RMB [7][12]. - The company’s overall revenue is expected to grow from 2.32 billion RMB in 2024 to 3.29 billion RMB in 2027, reflecting a steady growth trajectory [12][13].

Investment Rating - The investment rating for the company is "Buy" and is maintained [9] Core Viewpoints - The acceleration of nuclear power construction is a key industry driver for growth, with the company's modular business share increasing, which is expected to enhance profitability. The expansion of the convertible bond project will bring new development momentum [2][6] Summary by Relevant Sections Industry Overview - The nuclear power construction in China is accelerating, with a total of 28 new nuclear power projects approved over the past seven years, totaling 56 units. The number of approved and under-construction nuclear power units has reached 54, maintaining China's position as the world leader in nuclear power [7] Company Analysis - The company has a competitive advantage in modular manufacturing, which allows for the prefabrication and pre-assembly of large, complex devices, leading to cost and quality control benefits. Recent contracts, such as the 226 million yuan project for the Ningde Phase II modules, highlight this advantage [12] - The company's shareholder, China General Nuclear Power Group, may facilitate positive changes, such as an increase in modularization and progress in nuclear qualifications [12] - The company's nuclear gas separation devices contribute to its valuation and thematic flexibility, with significant involvement in fusion energy projects [12] Financial Performance - In the first three quarters, the company reported a revenue of 1.983 billion yuan, a year-on-year decrease of 23.44%, and a net profit of 178 million yuan, down 11.15%. However, the decline in profit was less than that of revenue, attributed to improved gross margins and reduced credit impairment losses [12] - The company is expanding its modular production capacity significantly, with the new convertible bond project covering an area of 487,800 square meters, which is 3.17 times the size of its main production base [12]

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Insights - In December 2025, the company sold 399,000 vehicles, a year-on-year decrease of 17.3% and a month-on-month decrease of 13.3%. However, the total sales for 2025 reached 4.508 million vehicles, representing a year-on-year increase of 12.3% [2][11] - Despite industry pressures, the company's self-owned brands achieved significant year-on-year growth, with December sales for SAIC Passenger Cars reaching 97,000 units, up 25.2% year-on-year. The sales for the entire year of 2025 for self-owned brands were 887,000 units, an increase of 25.4% [11] - The company launched several new models in December, including the Buick flagship MPV and the new MG4 semi-solid battery model, which are expected to enhance sales performance [11] Summary by Sections Overall Performance - December total sales were 399,000 vehicles, down 17.3% year-on-year and down 13.3% month-on-month. The total sales for 2025 were 4.508 million vehicles, up 12.3% year-on-year. The company's reforms have led to a stabilization and recovery in sales [11] Self-owned Brands - The self-owned brands performed well under industry pressure, with December sales of 97,000 units, up 25.2% year-on-year. The total sales for 2025 reached 887,000 units, an increase of 25.4% [11] New Energy and Overseas Sales - December sales for new energy vehicles were 144,000 units, down 6.6% year-on-year and down 31.3% month-on-month. The total sales for 2025 were 1.643 million units, up 33.1% year-on-year. Overseas sales in December were 101,000 units, up 0.2% year-on-year [11] Joint Ventures - December sales for SAIC Volkswagen were 88,000 units, down 32.4% year-on-year, while SAIC General's sales were 48,000 units, down 25.4% year-on-year. The total sales for 2025 for SAIC Volkswagen were 1.024 million units, down 10.8% [11] Internal Reforms and Future Outlook - The company is advancing internal reforms and enhancing cooperation with Huawei to accelerate its smart transformation. The expected net profits for 2025 and 2026 are projected to be 10.5 billion and 12.2 billion yuan, respectively, with corresponding P/E ratios of 16.7X and 14.4X [11]

Investment Rating - The investment rating for the company is "Buy" [7][13] Core Insights - The company is accelerating its innovation pipeline with 14 Class I innovative drug projects, including dual-target small molecules and biopharmaceuticals, with expectations of 2-3 innovative drugs entering clinical research each year over the next three years [4] - The company has achieved significant overseas certifications for its generic drugs, which is expected to drive a turnaround in performance [8] - The company experienced a decline in revenue and net profit in 2025, but is projected to see improvement in 2026 due to anticipated growth in overseas business and marginal improvements in domestic generic drug procurement [5] Financial Summary - As of Q1-Q3 2025, the company reported revenue of 742 million yuan, a decrease of 12.92%, and a net profit attributable to shareholders of -50.81 million yuan, a decline of 122.35% [5] - Revenue projections for 2025-2027 are 1.196 billion yuan, 1.446 billion yuan, and 1.742 billion yuan, respectively, with net profits expected to be 91 million yuan, 201 million yuan, and 300 million yuan [9][10] - The company’s PE ratios for 2025, 2026, and 2027 are projected to be 83.03, 37.57, and 25.10, respectively [5][9]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The report highlights the introduction of a stock incentive plan aimed at achieving significant profit growth from 2026 to 2028, with targets set for net profit growth and return on equity [6] - The report anticipates a reduction in industry capital expenditure cycles, which is expected to positively impact the company's pricing flexibility in 2026 [6] - The company is accelerating its layout in specialty fabrics, which is expected to lead to breakthroughs in the market [6] Financial Data and Profit Forecast - Total revenue projections for the company are as follows: - 2024: 15,856 million - 2025: 18,577 million - 2026: 20,317 million - 2027: 23,155 million - Year-on-year growth rates for total revenue are projected at 6.6% for 2024, 19.5% for 2025, 17.2% for 2026, and 14.0% for 2027 [5] - Net profit attributable to the parent company is forecasted to be: - 2024: 2,445 million - 2025: 3,676 million - 2026: 4,733 million - 2027: 5,241 million - The report indicates a significant increase in net profit growth rates, with 67.5% for 2025 and 28.7% for 2026 [5] - The report projects earnings per share to be: - 2024: 0.61 - 2025: 0.92 - 2026: 1.18 - 2027: 1.31 [5] Industry Insights - The report notes that the capital expenditure cycle in the fiberglass industry is nearing its end, with a projected net increase in capacity of only 27,000 tons for 2026 [6][8] - The report indicates that the industry inventory levels have stabilized, suggesting a healthy absorption of new capacity [6][9] - The company is expected to benefit from resilient demand in sectors such as wind energy, automotive, and home appliances, which are projected to maintain steady growth [6]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [7][13]. Core Insights - The company is entering the electronic cleanroom market, which is expected to open a second growth curve. It has established an electronic division in 2024 and won multiple projects, indicating strong growth potential in the semiconductor industry [4]. - The company has formed a strategic partnership with Jiufengshan Laboratory, enhancing its customer acquisition capabilities and integrating into the local semiconductor ecosystem [8]. - The company reported impressive performance in the first three quarters of 2025, with a revenue increase of 32.59% and a net profit increase of 211.46%, driven by the completion of purification system projects [8]. Financial Performance and Forecast - The company forecasts revenues of 25.57 billion, 35.59 billion, and 46.77 billion yuan for 2025, 2026, and 2027 respectively, with net profits of 1.38 billion, 2.12 billion, and 3.35 billion yuan for the same years [5][9]. - The current price-to-earnings (P/E) ratios are projected to be 28.7, 18.8, and 11.9 for 2025, 2026, and 2027 respectively, indicating a decreasing trend in valuation multiples as earnings grow [5][9].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [1][11]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of 4.1 to 4.6 billion yuan in 2025, representing a year-on-year increase of 80.72% to 102.76%, with a median estimate of 4.35 billion yuan, reflecting a 91.63% increase [2]. - The growth is driven by the continuous explosion in demand for AI computing servers and data centers, significantly boosting the demand for high-end PCB products [2]. - The company anticipates a net profit of 1.28 to 1.78 billion yuan in Q4 2025, with a median of 1.53 billion yuan, marking a year-on-year increase of 178.18% [2]. Financial Projections - Total revenue is projected to grow from 1.32 billion yuan in 2023 to 7.065 billion yuan by 2027, with a compound annual growth rate (CAGR) of 82.62% [1]. - The net profit attributable to shareholders is forecasted to increase from 219.31 million yuan in 2023 to 1.5729 billion yuan in 2027, with a CAGR of 93.07% [1]. - The earnings per share (EPS) is expected to rise from 0.53 yuan in 2023 to 3.84 yuan in 2027, indicating strong profitability growth [1]. Market Dynamics - The thickness of AI PCBs is continuously increasing, leading to a rise in the demand for high-length-to-diameter ratio drill bits, which are essential for processing these advanced PCBs [3][4]. - The company is experiencing a significant increase in the consumption value of single-hole drill bits as PCB thickness upgrades, which enhances the overall cost and demand for these products [4]. - The company’s production capacity is leading the industry, with expectations to reach a monthly capacity of 1.2 billion drill bits by the end of 2025 and 1.8 billion by the end of 2026 [5].

浪潮软件：数字政府解决方案领先厂商，多领域数字化业务布局 IT 服务Ⅱ 浪潮软件（600756.SH） 证券研究报告/公司深度报告 2026 年 01 月 05 日 | 公司盈利预测及估值 | 增持（首次） | 评级： | 指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 2,553 | 1,870 | 1,645 | 1,567 | 1,540 | 分析师：苏仪 | 增长率 | 23% | -27% | -12% | -5% | -2% | yoy% | | 归母净利润（百万元） | 91 | 14 | -22 | 1 | 22 | 执业证书编号：S0740520060001 | 增长率 | 43% | -85% | -262% | 104% | 2,146% | yoy% | | Email：suyi@zts.com.cn | 每股收益（元） | 0 ...